Preclinical study demonstrates that CCT2 mediates cisplatin resistance in lung adenocarcinoma, highlighting a potential therapeutic target to overcome chemoresistance.
. The present findings identified CCT2 as a key mediator of cisplatin resistance in LUAD and provided potential therapeutic strategies to overcome chemotherapy resistance.
No takes yet. Share an insight, caveat, or question.
Mao et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: